Associated tags: Tumor microenvironment, ICOS, Immune system, LILRB2, Patient, Macrophage, ILT4, Therapy, PD-1, CCR8, Gilead Sciences, Cancer, Fourth, fifth, and sixth derivatives of position, Security (finance), Sale
Locations: CAMBRIDGE, MA, US, GILEAD, SWITZERLAND, BOSTON
The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023.
Key Points:
- The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023.
- As of the expiration of the offer, 36,367,727 shares of Jounce common stock had been validly tendered and not validly withdrawn from the tender offer, representing approximately 69.09% of the outstanding shares of Jounce common stock.
- All conditions of the offer were satisfied or waived, and Concentra completed its acquisition of all outstanding shares of Jounce that were validly tendered and not validly withdrawn for the offer price.
- Following the closing of the tender offer, Concentra Merger Sub merged with and into Jounce and all shares of Jounce common stock that had not been validly tendered were converted into the right to receive the same $1.85 per share in cash plus one CVR per share (the “Merger”).
Life Storage,
Self storage,
Sale,
Blackstone,
Advertising,
David Heska Wanbli Weiden,
Cvent,
Fraud,
Therapy,
NYSE,
Security (finance),
Mars If you are a Life Storage shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a Life Storage shareholder, click here to learn more about your rights and options .
- If you are a Heska shareholder, click here to learn more about your rights and options .
- Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
NOT,
FOR,
Concentra,
Acquisition,
LAWS,
Therapy,
Holding company,
Cryptocurrency,
Fourth, fifth, and sixth derivatives of position CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination").
Key Points:
- CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination").
- On March 27, 2023, Jounce notified Redx of the withdrawal of its recommendation in favor of the Redx Business Combination and termination of the co-operation agreement dated February 23, 2023 between Jounce and Redx.
- Given that Jounce’s Board of Directors has withdrawn its recommendation to proceed with the Redx Business Combination, Jounce believes it is unlikely that Jounce stockholders would support the Redx Business Combination, which is a condition to closing the transaction.
- As a result, Jounce will not be convening a Jounce meeting of stockholders to consider the Redx Business Combination.
BALA CYNWYD, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
Key Points:
- BALA CYNWYD, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
- If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
- Under the terms of the deal, Berkshire Grey will be acquired by SoftBank Group Corp. and its affiliate (together, “SoftBank”).
- Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.
Workforce,
NOT,
AIM,
CVR,
FOR,
Business,
Concentra,
Tail,
Sale,
Acquisition,
LAWS,
Patient,
SELECT,
LP,
Therapy,
Pharmaceutical industry,
Fourth, fifth, and sixth derivatives of position CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the “CVR”).
Key Points:
- The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce’s closing share price immediately prior to the March 14, 2023 public disclosure of Concentra’s acquisition proposal.
- Jounce’s Board of Directors is no longer recommending the proposed all-share merger transaction (the “Redx Business Combination”) with Redx Pharma Plc (AIM:REDX) (“Redx”).
- In conjunction with the merger agreement, Jounce is implementing a workforce reduction of approximately 84% of its employees.
- This reduction is expected to be completed within the next month and Jounce will incur restructuring costs totaling approximately $6.5 million1.
Class Action Lawsuit,
Professional Services,
Legal,
Concentra,
Fraud,
Advertising,
Sale,
Security (finance),
Fourth, fifth, and sixth derivatives of position Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash per share plus a non-tradeable contingent value right is fair to Jounce shareholders.
Key Points:
- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash per share plus a non-tradeable contingent value right is fair to Jounce shareholders.
- On behalf of Jounce shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
- Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
PLLC,
Wall Street,
Black Hawk,
Fraud,
Therapy,
Centerbridge Partners,
Security (finance),
Bank,
Fourth, fifth, and sixth derivatives of position Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Key Points:
- Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
- Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
- Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
- Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.
POC,
Therapy,
Immunoglobulin G,
LILRB2,
Pembrolizumab,
Neoplasm,
Platinum,
Patient,
PD-L1,
RECIST,
Ligand,
PD-1,
Ovarian cancer,
Pharmaceutical industry The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors.
Key Points:
- The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors.
- A data review was conducted on March 15, 2023 to assess the potential to achieve proof-of-concept (POC) in the ovarian cancer combination cohort of the INNATE trial.
- In this cohort, 35 patients with third- and fourth-line platinum resistant ovarian cancer were treated with JTX-8064 and Jounce’s PD-1 inhibitor, pimivalimab.
- The combination was well tolerated with
Retrieved on:
Wednesday, March 15, 2023
Apollo Global Management,
Monteverde,
Sale,
Therapy,
NYSE,
Blackstone Inc.,
MNTV,
CVT,
Symphony Technology Group,
Empire,
Univar Solutions,
Security (finance) It is free and there is no cost or obligation to you.
Key Points:
- It is free and there is no cost or obligation to you.
- Under the terms of the agreement, MNTV shareholders will receive $9.46 in cash per share they own.
- Under the terms of the agreement, UNVR shareholders will receive $36.15 in cash per share they own.
- Cvent Holding Corp. (NASDAQ: CVT ), relating to its sale to equity funds managed by Blackstone Inc. Click here for more information: https://www.monteverdelaw.com/case/cvent-holding-corp .
Retrieved on:
Wednesday, March 15, 2023
Cyprus Securities and Exchange Commission,
Tail,
LP,
NOT,
AIM,
LAWS,
FOR,
Proposal,
Schedule,
Fourth, fifth, and sixth derivatives of position CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (“the Proposal”) to acquire 100% of the equity of Jounce. According to the Schedule 13D filed today with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital1 is currently approximately a 10.2% shareholder of Jounce.
Key Points:
- CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (“the Proposal”) to acquire 100% of the equity of Jounce.
- According to the Schedule 13D filed today with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital1 is currently approximately a 10.2% shareholder of Jounce.
- The transaction is anticipated to be completed during the second quarter of 2023, subject to necessary regulatory and shareholder approvals.
- The Board is committed to acting in the best interests of all shareholders, consistent with its fiduciary duties.
